ASCP Corner: All Antipsychotics Are Equal, but Some Are More Equal Than Others
J Clin Psychiatry 2009;70(3):429-430
© Copyright 2016 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
One of the “atypical” features of second-generation antipsychotics
(SGAs) that was quickly appreciated by clinicians
and patients shortly after their introduction was that these
medications were shown to elicit fewer extrapyramidal side
effects than the first-generation antipsychotics (FGAs). Early
head-to-head comparisons of some first-line SGAs with FGAs
in patients with schizophrenia also demonstrated better efficacy
in terms of overall symptom reduction in studies comparing
risperidone and olanzapine with haloperidol. However, later
studies failed to demonstrate the superiority of SGAs over
FGAs in effectiveness or safety.